Triple-action cancer jab amivantamab shrinks tumors in over a third of patients in international trial
By
Andrew Gregory
Crispy enough to crunch, soft enough to enjoy. A good bake.
Summary
An international trial across 11 countries shows that a triple-action cancer injection called amivantamab can shrink or completely eradicate tumors in patients whose cancer had spread, returned, or failed to respond to other treatments. The drug shrank tumors in over a third of patients, with 15 patients experiencing complete tumor disappearance. Doctors describe the results as 'unprecedented' and note dramatic changes were seen within weeks, particularly in patients resistant to chemotherapy and immunotherapy.
Key quotes
· 4 pulledDoctors have hailed 'unprecedented' trial results that show a triple-action cancer jab can eradicate entire tumours in patients.
The jab, called amivantamab, shrank the tumours of more than a third of patients, with dramatic changes seen within weeks.
In 15 of them, doctors found the drug had melted away their tumours altogether.
Jab brought 'unprecedentedly strong responses' in patients whose disease had become resistant to chemotherapy and immunotherapy
You might also wanna read
Engineered immunotherapy drug eliminates aggressive metastatic cancers in clinical trial
Researchers at Rockefeller University have developed an engineered CD40 agonist antibody that successfully eliminated aggressive metastatic
rockefeller.edu·8mo ago
TAR-200 Drug System Eliminates Bladder Cancer in 82% of Resistant Patients
A new drug-releasing system, TAR-200, has shown remarkable success in treating high-risk non-muscle-invasive bladder cancer, eliminating tum
news.keckmedicine.org·9mo ago
Personalized mRNA Cancer Vaccine Shows 49% Risk Reduction at 5-Year Follow-up
Moderna and Merck report promising 5-year follow-up results for their personalized mRNA cancer vaccine combined with Keytruda immunotherapy.
arstechnica.com·4mo ago